gyti_1u.htm

0001477932-21-001321.txt : 20210309 0001477932-21-001321.hdr.sgml : 20210309 20210309104527 ACCESSION NUMBER: 0001477932-21-001321 CONFORMED SUBMISSION TYPE: 1-U PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20210226 ITEM INFORMATION: Other Events FILED AS OF DATE: 20210309 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GRAYSTONE COMPANY, INC. CENTRAL INDEX KEY: 0001510524 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 273051592 STATE OF INCORPORATION: CO FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 1-U SEC ACT: 1933 Act SEC FILE NUMBER: 24R-00377 FILM NUMBER: 21724490 BUSINESS ADDRESS: STREET 1: 401 E. LAS OLAS BLVD #130-321 CITY: FORT LAUDERDALE STATE: FL ZIP: 33301 BUSINESS PHONE: 954-271-2704 MAIL ADDRESS: STREET 1: 401 E. LAS OLAS BLVD #130-321 CITY: FORT LAUDERDALE STATE: FL ZIP: 33301 FORMER COMPANY: FORMER CONFORMED NAME: Graystone Co DATE OF NAME CHANGE: 20110118 1-U 1 gyti_1u.htm FORM 1-U gyti_1u.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 1-U

CURRENT REPORT

Pursuant Regulation A of the Securities Act of 1933

February 26, 2021

(Date of Report (Date of earliest event reported))

THE GRAYSTONE COMPANY, INC.

(Exact name of registrant as specified in its charter)

COLORADO		86-2416093
(State or other jurisdiction of incorporation)		(IRS Employer Identification No.)

401 E. Las Olas Blvd #130-321

Fort Lauderdale, FL

33301

(Address of principal executive offices)

(ZIP Code)

(954) 271-2704

(Registrant’s telephone number, including area code)

Common Shares

(Title of each class of securities issued pursuant to Regulation A)

Item 9. Other Events

On February 26, 2021, the Company issued a press release. A copy of the press release is attached hereto and incorporated herein by reference in its entirety as Exhibit 15.1. On March 4, 2021 attached hereto and incorporated herein by reference in its entirety as Exhibit 15.2.

15.1	Press Release Dated February 26, 2021

15.2	Press Release Dated March 4, 2021

Safe Harbor Statement

The information furnished in Form 1-U is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section, and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

This Current Report on Form 1-U contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934. You can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “projects,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties, including those described under the section entitled “Risk Factors” in our Offering Statement on Form 1-A dated July 23, 2018, filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in our periodic filings and prospectus supplements filed with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

SIGNATURES

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	THE GRAYSTONE COMPANY, INC.

Date: March 9, 2021	By:	/s/ Anastasia Shishova
	Name:	Anastasia Shishova
	Title:	CEO

ADD EXHB 2 gyti_ex151.htm PRESS RELEASE gyti_ex151.htm

EXHIBIT 15.1

Graystone Company Announces Reverse Merger with NutraGyst, Inc.

Fort Lauderdale, FL – March 1, 2021 – Graystone Company, Inc. (OTC: GYST) announced today that it has completed the reverse merger with NutraGyst, Inc.

After the reverse merger, we are now primarily focused on developing products for our Longevity and Wellness line. We intend to create products for this line using original supplement blends formulated by the Company based on an innovative and sustainable approach. We intend to design and produce products with high-end, quality ingredients that are plant based, Non-GMO, gluten and lactose-free. It is planned that these products will be distributed by NutraGyst, Inc.

The Company is working to finalize the product formulas. The Company is also currently developing the packaging of these products for marketing and branding purposes. We estimate that it we will launch our initial product in July/August 2021.

About The Graystone Company, Inc.

Graystone Company develops products for planned product line for Longevity and Wellness. The Graystone Company, Inc. (OTC PINK:GYST) is headquartered in Fort Lauderdale, FL., and can be reached at www.thegraystonecompany.com or by phone at (954) 271-2704.

Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.

For more information:

Graystone Company

Email: info@thegraystonecompany.com

Phone: (954) 271-2704

ADD EXHB 3 gyti_ex152.htm PRESS RELEASE gyti_ex152.htm

EXHIBIT 15.2

Graystone Company Announces Initial Product, Fucoidan Longevity Booster

Fort Lauderdale, FL – March 4, 2021 – Graystone Company, Inc. (OTC: GYST) announced today its initial product to be launched, “Fucoidan Longevity Booster.”

What is the “Fucoidan Longevity Booster”:

It is a powerful anti-inflammatory antioxidant blend with rejuvenating properties. The main ingredient of this proprietary blend is fucoidan, a complex polysaccharide found in many species of brown seaweed. We will use a nano Fucoidan Extract which increases absorption rates up to 5 times.

What is Fucoidan?

Fucoidans occur naturally in the cell walls of brown seaweeds and function to protect the plant from water-borne pathogens and other environmental challenges. Fucoidans are long chain polysaccharides characterized by a complex molecular structure and varying degrees of sulfation and acetylation. Our Nano Fucoidan Extract is produced from Okinawan mozuku fucoidan which is derived through a patented manufacturing process.

What research has been done on Fucoidan?

According to information published by Memorial Sloan Kettering Cancer Center as of January 2021, studies on fucoidan suggest that it can prevent the growth of cancer cells and has antiviral, neuroprotective, and immune-modulating effects. (Memorial Sloan Kettering Cancer Center).

Additionally, more than 2000 independent, peer-reviewed research papers have been published on the bioactive properties of fucoidan. This extensive body of evidence includes comprehensive in vitro investigations, animal studies and human clinical trials.

Extensive research has been undertaken on the immune-modulatory properties of fucoidan. Published papers have reported that fucoidan may exert a range of beneficial effects on the human immune system, including the reduction of allergic responses and the activation of dendritic cells, natural killer cells and T cells. It has also been shown that fucoidan has the potential to boost important anti-viral and anti-tumour responses. Research into the therapeutic properties of fucoidan has largely focused on the key health indications identified below.

Boosting immune responses

Immune responses to vaccines or infections can be weakened or inadequate, particularly during ill health and in older people. In a clinical setting, ingestion of fucoidan was shown to help boost the immune responses to seasonal influenza vaccinations (Negishi, 2013). The ingestion of fucoidan has also been shown to increase the anti-pathogenic activity of granulocytes (white blood cells) and macrophages (there are involved in detection, phagocytosis and destruction of bacteria and other harmful organisms) in healthy people (Myers, 2011). Increased immune activity after fucoidan ingestion can even eliminate the tropical protozoan parasite Leishmania, as seen in a mouse model (Kar, 2011). Fucoidans can also promote the maturation of dendritic cells, activate NK cells and promote cytotoxic activity (Zhang, 2015).

Cancer

Fucoidan is most widely known and used for its potential anti-cancer properties. A considerable amount of research has been undertaken in this area, with some researchers proposing that fucoidan not only increases patient wellbeing, but also assists in the treatment of disease. The potential for fucoidan as an anti-cancer agent is explored in several review publications, including those by Fitton (2015), Kwak (2014) and Lowenthal (2014).

Anti-inflammatory

Fucoidan shows potential therapeutic anti-inflammatory activity, particularly as a selectin blocker. Fucoidan has potential to be very effective in addressing systemic inflammation, as well as local inflammation in the digestive tract when orally ingested and on the skin when applied topically. (Maruyama, 2015) The mechanisms of action may include inhibition of inflammatory enzymes and increased integrity of cellular junctions. Fucoidan may have therapeutic potential in the treatment of rheumatoid arthritis. (Shu, 2015)

Anti-ageing

Research on fucoidan has shown a marked effect on ageing related processes. Fucoidan can potentially reverse ageing in endothelial stem cells (Lee, 2015) and is known to increase sirtuin levels in cell models (Fitton, 2015). In addition to inhibiting key enzymes associated with human ageing processes, research has demonstrated that fucoidan may promote vascular health and stimulate immune responses. It has also been shown to exhibit neuroprotective properties in animal models.

In addition to the above key areas, there are many other potential niche applications for fucoidan (Fitton, 2015). These include:

● Antibiotic potentiation (Lee, 2013)

● Kidney disease (Jia, 2016)

● Mesenchymal stem cell transplants (Lee, 2016)

● Venom neutralisation (Azofeifa, 2008)

● Anti-prion activity (Doh-Urah, 2007)

● Drug release (Yu, 2015)

● Biomaterials (Fitton, 2015)

● Animal health (O’Shea, 2014)

Expected Launch Date

The Company is working to finalize the product formulas for its Fucoidan Longevity Booster . We estimate that it we will launch our Fucoidan Longevity Booster in July/August 2021.

This information is of a general nature only and has not been evaluated by the FDA or other regulatory body. Our fucoidan products are not intended to treat, cure or prevent any disease and recipients of this information must exercise their own judgement in determining the appropriateness for a particular purpose.

About The Graystone Company, Inc.